Question 1

What are the potential benefits of combining gefitinib with anlotinib for my condition?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Gefitinib in Combination With Anlotinib or Placebo in Previously Untreated EGFR-mutant NSCLC clinical trial (NCT04028778). Contact the study team or your healthcare provider for specific answers.

Question 2

How does this treatment compare to standard options available for my cancer?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Gefitinib in Combination With Anlotinib or Placebo in Previously Untreated EGFR-mutant NSCLC clinical trial (NCT04028778). Contact the study team or your healthcare provider for specific answers.

Question 3

What side effects should I expect from this combination therapy?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Gefitinib in Combination With Anlotinib or Placebo in Previously Untreated EGFR-mutant NSCLC clinical trial (NCT04028778). Contact the study team or your healthcare provider for specific answers.

Question 4

How often will I need to visit the clinic during the trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Gefitinib in Combination With Anlotinib or Placebo in Previously Untreated EGFR-mutant NSCLC clinical trial (NCT04028778). Contact the study team or your healthcare provider for specific answers.

Question 5

What tests will I need to undergo while participating in this trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Gefitinib in Combination With Anlotinib or Placebo in Previously Untreated EGFR-mutant NSCLC clinical trial (NCT04028778). Contact the study team or your healthcare provider for specific answers.

Question 6

Are there any costs or travel requirements I should be aware of?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Gefitinib in Combination With Anlotinib or Placebo in Previously Untreated EGFR-mutant NSCLC clinical trial (NCT04028778). Contact the study team or your healthcare provider for specific answers.

What this study is about